BEIJING, Dec. 10 /PRNewswire-Asia/ -- Lotus Pharmaceuticals, Inc. (“Lotus” or the “Company”) a growing developer and producer of prescription drugs and licensed national seller of pharmaceutical products in the People’s Republic of China (“PRC”), today reported that effective December 1, 2009, Liang Fang, a controlled operating entity of Lotus, appointed Mr. Jinzhong HAN to be General Manager of the Company’s Over-the-Counter Drug division (“OTC Division”).
Mr. Han has over 20 years of medical sales experiences. Prior to joining Liang Fang, Mr. Han was General Manager of the OTC Division of Tianjin Taiping Pharmaceutical Company for two years. Prior to such time, he served approximately seven years as Vice General Manager and Chief of Marketing Officer of Beijing Yongkang Pharmaceutical Company. Mr. Han has a bachelor degree of business management from Air Force Institute of Logistics.
“Mr. Han has strong management skills in medical sales and marketing and logistics, proven with his previous tenure in both state-owned enterprises and private entities,” said Dr. Zhong Yi Liu, Chairman and Chief Executive Officer of the Company. “We are bringing a strong leader to our OTC Division to further grow the OTC Division and lead a team of approximately 40 employees, of which approximately half of such employees are medical sales professionals. We are confident that Mr. Han’s expertise in the area will assist the expansion of our OTC business into 2012, as well as efficiency in delivery of services to drug stores in Beijing.”
About Lotus Pharmaceuticals, Inc. (http://www.lotuspharma.com )
Lotus Pharmaceuticals, Inc. is a growing developer and producer of prescription drugs and a licensed national seller of pharmaceutical items in the People’s Republic of China. Lotus operates Liang Fang Pharmaceutical, Ltd. and En Ze Jia Shi Pharmaceutical, Ltd. Lotus’ current drug development pipeline is focused on the treatment of cerebro-cardiovascular disease, asthma, and diabetes. More than 8,000 products are sold by Liang Fang directly and indirectly through its national sales channels to hospitals, clinics and drugs stores in 30 provinces.
Safe Harbor Statement
This press release contains “forward-looking statements” within the meaning of the “safe-harbor” provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, without limitation, any statement that may predict, forecast, indicate, or imply future results, performance or achievements, and may contain the words “estimate,” “project,” “intent,” “forecast,” “anticipate,” “plan,” “planning,” “expect,” “believe,” “will likely,” “should,” “could,” “would,” “may,” or words or expressions of similar meaning. Such statements are not guarantees of future performance and could cause the actual results of the Company to differ materially from the results expressed or implied by such statements, including, but not limited to, changes from anticipated levels of sales, future national or regional economic and competitive and regulatory conditions, changes in relationships with customers, access to capital, increased costs, difficulties in developing and marketing new products, marketing existing products, customer acceptance of existing and new products, the time to get new drugs approved by the State Food and Drug Administration and other factors. Additional information regarding risks can be found in the Company’s Annual Report on Form 10K and its older filings with the SEC. Accordingly, although the Company believes that the expectations reflected in such forward-looking statements are reasonable, there can be no assurance that such expectations will prove to be correct. The Company has no obligation to update the forward-looking information contained in this press release.
CONTACT: Lotus Pharmaceuticals, Inc., Yan ZENG, CFO, +86-10-6389-9868, or
zy@lotuspharma.com
Web site: http://www.lotuspharma.com/
